Ascendis Pharma A/S (FRA:A71)
Germany
· Delayed Price · Currency is EUR 171.00
-1.00 (-0.58%)
At close: Dec 4, 2025
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
€635,740
Profits / Employee
€229,047
Market Cap
10.93B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 318,000 |
| Allianz SE | 156,626 |
| Deutsche Telekom AG | 198,194 |
| Siemens Energy AG | 103,000 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Rheinmetall AG | 28,539 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Ascendis Pharma News
- 7 days ago - FDA Extends Review for Ascendis Pharma's (ASND) TransCon CNP - GuruFocus
- 7 days ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 7 days ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 9 days ago - Is the Market Bullish or Bearish on Ascendis Pharma AS? - Benzinga
- 9 days ago - FDA Extends Decision Date For TransCon CNP In Pediatric Achondroplasia - Nasdaq
- 10 days ago - Ascendis Pharma (ASND) Faces FDA Review Extension for TransCon CNP - GuruFocus
- 10 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 10 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire